ArticleRSC advances2018
Directed evolution of mevalonate kinase in
Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Structural basis of mevalonate pathway regulation by feedback inhibition of mevalonate kinase.The Journal of biological chemistry · 2026Article
- Isolation and identification of Alcaligenes faecalis W2-3 with high-yield production of dimethyl disulfide.Scientific reports · 2025Article
- Enhancing limonene production by probing the metabolic network through time-series metabolomics data.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Biotechnological production of terpenoids using cell factories.Frontiers in pharmacology · 2025Review
- Characterization of novel mevalonate kinases from the tardigrade Ramazzottius varieornatus and the psychrophilic archaeon Methanococcoides burtonii.Acta crystallographica. Section D, Structural biology · 2024Article
- Functional diversity and metabolic engineering of plant-specialized metabolites.Life metabolism · 2022Review
- Carotenoids in Drug Discovery and Medicine: Pathways and Molecular Targets Implicated in Human Diseases.Molecules (Basel, Switzerland) · 2022Review
- De novo biosynthesis of τ-cadinol in engineered Escherichia coli.Bioresources and bioprocessing · 2022Article
- Alternative metabolic pathways and strategies to high-titre terpenoid production inNatural product reports · 2022Review
- Metabolic engineering for high yield synthesis of astaxanthin in Xanthophyllomyces dendrorhous.Microbial cell factories · 2021Review
- Improve the production of D-limonene by regulating the mevalonate pathway of Saccharomyces cerevisiae during alcoholic beverage fermentation.Journal of industrial microbiology & biotechnology · 2020Article
- Modular engineering for microbial production of carotenoids.Metabolic engineering communications · 2020Review
- Correction to: Enhancement of the catalytic activity of Isopentenyl diphosphate isomerase (IDI) from Saccharomyces cerevisiae through random and site-directed mutagenesis.Microbial cell factories · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lycopene is a terpenoid pigment that has diverse applications in the fields of food and medicine. Metabolic engineering in microbial hosts has shown that mevalonate kinase (MK, EC2.7.1.366) is one of the rate-limiting enzymes in the lycopene synthetic pathway. In this study, a directed evolution strategy in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.